As 2023 draws to a close, the pharma industry finds itself at an inflection point. On the one hand, stubbornly high inflation rates, a dearth of talent, supply chain hurdles, and a more challenging regulatory climate threaten profitability. But on the other, the rapid advances in areas ranging from cell and gene therapy and IT…

Global supply chains have arguably seen more disruption in the past year than they have seen in decades. Pharmaceutical supply chains were especially vulnerable in the early days of the COVID-19 pandemic, prompting a rethink of supply chain management for the industry. Another wrinkle is a recent executive order from President Biden, which prompted a…